Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Glioblastoma
Clinical trial register · Netherlands

Glioblastoma Trials in Netherlands, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Netherlands and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3171 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
3171
Studies in scope
all four open statuses
1789
Recruiting now
open to new participants
601
Lead sponsors
across recruiting studies
Top sites
Rotterdam 14 The Hague 11 Utrecht 7 Amsterdam 5 Maastricht 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Glioblastoma trials in Netherlands

22 of 3171 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Netherlands
Start
Recruiting
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
NCT07100730Neoplastic Disease, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
50
Amsterdam, Utrecht
2025-11-02
Recruiting
Erasmus Medical Center
Not applicable
120
Amsterdam, Leiden, Rotterdam, Utrecht
2025-01-15
Recruiting
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
Nationwide Children's Hospital
Observational
350
Utrecht
2024-08-02
Not yet open
FET-PET-Guided Management of Pseudoprogression in Glioblastoma
NCT06480721Glioblastoma, Radionecrosis of Brain
Veerle Ruijters
Not applicable
144
Amsterdam, Enschede, Groningen, Maastricht, Nijmegen, Rotterdam, The Hague, Utrecht
2024-08
Active, closed
Ivy Brain Tumor Center
Phase 3
450
Maastricht, Utrecht
2024-06-19
Recruiting
Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques
NCT06623565Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
Amsterdam UMC, location VUmc
Not applicable
30
Amsterdam
2024-04-01
Active, closed
CarThera
Phase 3
560
Rotterdam, The Hague
2024-01-29
Recruiting
Erasmus Medical Center
Not applicable
53
Rotterdam
2024-01-03
Active, closed
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
NCT05450744Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 1
12
Utrecht
2023-04-01
Recruiting
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
NCT06283927Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain
Jasper Gerritsen
Observational
464
Rotterdam, The Hague
2023-01-01
Recruiting
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
NCT06146738Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
Jasper Gerritsen
Observational
1,015
Rotterdam, The Hague
2023-01-01
Recruiting
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
NCT06146725Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
Jasper Gerritsen
Observational
564
Rotterdam, The Hague
2023-01-01
Recruiting
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
NCT06273176Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant
Erasmus Medical Center
Observational
225
Rotterdam, The Hague
2023-01-01
Not yet open
Erasmus Medical Center
Observational
325
Alkmaar, Enschede, Maastricht, Rotterdam, The Hague, Tilburg
2023-01-01
Active, closed
Erasmus Medical Center
Not applicable
10
Rotterdam
2022-07-14
Recruiting
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
NCT06118723Glioblastoma, High-grade Glioma, Glioblastoma, IDH-wildtype, Glioblastoma, IDH-mutant
Jasper Gerritsen
Observational
784
Rotterdam, The Hague
2022-01-01
Active, closed
Nerviano Medical Sciences
Phase 1/2
150
Rotterdam
2021-12-01
Recruiting
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm
DrugONC206
Sabine Mueller, MD, PhD
Phase 1
208
Utrecht
2021-08-23
Active, closed
Maastricht Radiation Oncology
Observational
60
Maastricht
2021-04-10
Active, closed
Supramarginal Resection in Glioblastoma
NCT04243005Glioblastoma
St. Olavs Hospital
Not applicable
90
Rotterdam, The Hague
2020-07-01
Recruiting
The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
NCT03861299Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Astrocytoma, Grade IV
Jasper Gerritsen
Not applicable
246
Tilburg, Rotterdam, The Hague, Groningen
2019-04-01
Recruiting
Surgery for Recurrent Glioblastoma
NCT02394626Glioblastoma
Insel Gruppe AG, University Hospital Bern
Phase 2
120
Amsterdam, Nijmegen, The Hague
2015-05-01
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Dutch investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-netherlands/condition/glioblastoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Netherlands and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,171 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Glioblastoma.

How many Glioblastoma trials are recruiting in Netherlands?

13 of the 22 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Glioblastoma), 22 studies
PhaseStudiesRecruitingShare
Observational8636.4%
Not applicable7431.8%
Phase 33113.6%
Phase 1219.1%
Phase 1/2104.5%
Phase 2114.5%

Most active sponsors

Lead sponsors with the most studies (Glioblastoma)
Lead sponsorStudiesRecruiting
Erasmus Medical Center53
Jasper Gerritsen55
Telix Pharmaceuticals (Innovations) Pty Limited21
Amsterdam UMC, location VUmc11
CarThera10
Insel Gruppe AG, University Hospital Bern11
Ivy Brain Tumor Center10
Maastricht Radiation Oncology10
Nationwide Children's Hospital11
Nerviano Medical Sciences10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.